Skip to main content
Log in

Lead-time in prostate cancer screening (Finland)

Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objective: Lead-time in prostate cancer screening was estimated using data from the Finnish randomized, population-based trial. Methods: Lead-time was defined as the duration of follow-up needed to accrue the same expected number of incident prostate cancer cases in the absence of screening as detected in the initial screening round. Expected numbers were calculated using an age-cohort model. Results: Based on findings among 10,000 men screened in 1996–1997 with 292 screen-detected cancers, lead-time was estimated as approximately 5–7 years, depending on the reference rates used. This corresponds to a mean duration of the detectable preclinical phase (DPCP) of 10–14 years, given that the cancers were detected on average at the midpoint of the DPCP. Conclusions: The findings suggest that a screening interval substantially longer than the 2 years generally used for mammography screening is unlikely to cause a substantial loss of sensitivity. A long screening interval is further justified in order to diminish the extent of overdiagnosis, until mortality effects can be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. (1997) Cancer Incidence in Five Continents, vol. VII. Publ. No 143. Lyon: International Agency for Research on Cancer.

  2. Ross RK, Schottenfeld D (1996) Prostate cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention, 2nd edn. New York: Oxford University Press, pp. 1180-1206.

    Google Scholar 

  3. Auvinen A, Rietbergen J, Gohagen J, Denis L, Schro¨ der F (1996) Prospective evaluation plan for randomized trials of prostate cancer screening. J Med Screening 3: 97-104.

    Google Scholar 

  4. Chen J S, Prorok PC (1983) Lead time estimation in a controlled screening program. Am J Epidemiol 118: 740-751.

    Google Scholar 

  5. Walter SD, Day NE (1983) Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol 118: 865-886.

    Google Scholar 

  6. Ma¨ a¨ tta¨ nen L, Auvinen A, Stenman U-H, et al. (1999) European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 79: 1210-1214.

    Google Scholar 

  7. Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Acta Oncol 33: 365-369.

    Google Scholar 

  8. Smith DS, Catalona WJ, Herschman JD (1996) Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 276: 1309-1315.

    Google Scholar 

  9. Mettlin CJ, Murphy GP, Babaian RJ, et al. (1997) Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. Cancer 80: 1814-1817.

    Google Scholar 

  10. Lodding P, Aus G, Bergdahl S, et al. (1998) Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. J Urol 159: 899-903.

    Google Scholar 

  11. Schro¨ der FH, Kranse R, Rietbergen J, Hoedemaeker R, Kirkels W (1999) The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 35: 539-543.

    Google Scholar 

  12. Chodak GW, Thisted RA, Gerber GS, et al. (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242-248. 284 A. Auvinen et al.

    Google Scholar 

  13. Breslow N, Chan CW, Dhom G, et al. (1977) Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 20: 680-688.

    Google Scholar 

  14. Ries LAG, Eisner MP, Kosary CL, et al., eds (2001) SEER Cancer Statistics Review, 1973-1998. Bethesda, MD: National Cancer Institute.

    Google Scholar 

  15. Cancer Incidence in Finland 1997-1998 (2000). Helsinki: Cancer Society of Finland. Available also from http:/www.cancerregistry.fi/.

  16. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J (1994). Serum concentrations of prostate specific antigen and its complex with alpha-1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344: 1594-1598.

    Google Scholar 

  17. Whittemore AS, Keller JB, Betensky R (1991) Low-grade, latent prostate cancer volume: predictor of clinical incidence? J Natl Cancer Inst 83: 1231-1235.

    Google Scholar 

  18. Whittemore AS, Lele C, Friedman GD, et al. (1995) Prostatespecific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 87: 354-360.

    Google Scholar 

  19. Morrell CH, Pearson JD, Carter HB, et al. (1995) Estimating unknown transition times using a piecewise nonlinear mixed effects model in men with prostate cancer. JAmStat Assoc 90: 45-53.

    Google Scholar 

  20. Etzioni R, Cha R, Feuer EJ, Davidov O (1998) Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 148: 775-785.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Auvinen, A., Määttänen, L., Stenman, UH. et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control 13, 279–285 (2002). https://doi.org/10.1023/A:1015040231402

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015040231402

Navigation